Czarnecka, Anna M <br/><br/>
Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer.  [electronic resource] 

 -  Future oncology (London, England)  2015 
 - 17-26 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1744-8301 
<br/><br/><label>Standard No.: </label>10.2217/fon.14.135  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Bone Marrow Cells--drug effects<br/>Carcinoma, Renal Cell--complications<br/>Humans<br/>Indoles--adverse effects<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--chemically induced<br/>Male<br/>Middle Aged<br/>Molecular Targeted Therapy--adverse effects<br/>Niacinamide--adverse effects<br/>Phenylurea Compounds--adverse effects<br/>Pyrroles--adverse effects<br/>Sorafenib<br/>Sunitinib<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors